Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Updated and amended notice of allowance has been posted on USPTO website. Related information can be found using the following link and entering application number 10607434. Documents can be viewed in PDF format by clicking on the image file wrapper tab.
This is very good news IMO
http://portal.uspto.gov/external/portal/home
BIPH have a look folks!!
Lot's to like here!!
Dilutive financing ended
Important patent approval achieved
Deep patent portfolio and pipeline
Insider buying
Huge market potential
Reasonable cash position
Accumulation underway .011-.015
AS maxed out
AS 250mm OS 243mm
A little buying interest and this one will rock!!
BIPH have a look folks!!
Lot's to like here!!
Dilutive financing ended
Important patent approval achieved
Deep patent portfolio and pipeline
Insider buying
Huge market potential
Reasonable cash position
Accumulation underway .011-.015
AS maxed out
AS 250mm OS 243mm
A little buying interest and this one will rock!!
More funding/debt/dilution scheduled for tomorrow?
$8,650,000 Securities Purchase Agreement – On July 29, 2008, we entered into a Securities Purchase Agreement (the “July 29 SPA”) with YA Global, an accredited investor in the principal amount of $8,650,000. The July 29 SPA provides for the amount to be drawn through three separate secured convertible debentures (the “debentures”) in the amounts of $2,325,000, $2,325,000, and $4,000,000 respectively. The first debenture was issued on July 29, 2008. Upon the achievement of certain milestones, the remaining two debentures are scheduled to be issued on October 29, 2008 and January 2, 2009, respectively.
http://ih.advfn.com/p.php?pid=nmona&cb=1225225274&article=27769274&symbol=NB%5ENEOM
More coverage on airline boarding via cell phone.
http://www.msnbc.msn.com/id/21134540/vp/27418316#27418316
Here is a list of the "mysterious private owners" and their percentage ownership as of the SPA dated 10/2/07. Would you mind sharing your insight as to the mystery? It appears to me that Myotech ownership was fully disclosed.
http://www.sec.gov/Archives/edgar/data/1084000/000114420407052986/v089616_ex10-1.htm
"A man doesn't know what he knows until he knows what he doesn't know"
=DJ US Home Builders Push Bold New Fix For Housing Market
.
(This article was originally published Monday.)
By Jessica Holzer
Of DOW JONES NEWSWIRES
WASHINGTON (Dow Jones)--U.S. home builders, reeling from the worst housing downturn in decades, are pushing a bold new plan of tax benefits and mortgage subsidies to jump-start the market.
The proposal would revive two measures used to combat the housing slump of the 1970s - a generous tax credit for home purchases and a federal program to push down mortgage rates to below market levels.
Industry leaders will begin selling the plan, dubbed "fix housing first," to lawmakers as soon as this week in the hope of having it tacked onto stimulus legislation Democrats are likely to push after the election.
Home builders say that legislation, which would likely include an extension of unemployment benefits and infrastructure spending, won't pack any punch unless it contains measures to help the housing sector.
"We don't have a bridge crisis, we have a housing crisis in this country and it's bringing the economy down," said Ara Hovnanian, the president and CEO of home builder Hovnanian Enterprises Inc. (HOV).
Hovnanian and the chief executives of other large home builders Lennar Corp. (LEN), Centex Corp. (CTX) and Pulte Homes Inc. (PHM) were attempting to meet with lawmakers ahead of a Wednesday hearing in the House Ways and Means Committee on the economic stimulus legislation.
National Association of Home Builders President Jerry Howard said the industry would push for congressional action before the end of the year. "The housing industry is going to be united in suggesting that we fix housing before we fix anything else," he said.
The push comes just as the industry received some rare good news on Monday. Home sales jumped by 2.7% in September, the Commerce Department reported.
The industry is working on finalizing the details of the plan, which Howard describes as a "sort of resurrection" of the policies used during the last severe housing downturn.
In 1975, Congress passed a $2,000 temporary tax credit on all sales of new homes. The industry is pushing for a tax credit of at least $12,000 and up to a limit of $22,000, depending on median area home prices.
Home builders contend that a $7,500 tax credit for first-time home buyers that Congress passed this summer has been a disappointment, in part because beneficiaries must pay back the government over time. "It absolutely did not do anything for sales," Pulte Homes Chief Executive Richard Dugas said.
In addition, the industry wants to mimic a 1970s program in which the government corporation Ginnie Mae subsidized mortgage rates for some borrowers. Under the program, Ginnie Mae paid lenders full price for loans with below-market rates and then resold them at lower market prices, swallowing the difference.
Called Ginnie Mae Tandem, the program cut rates on 30-year fixed-rate mortgages from above 9% to 7.5%. Today, the largest home builders want the government to push rates on such mortgages, which are hovering around 6.25%, down to 2.99%.
Along with the tax credit, the move "would be a giant change" for the industry, Dugas said. Under the plan, both the tax credit and the mortgage subsidy would be temporary, lasting perhaps six to nine months, Howard said. Unlike in the 1970s, the incentives would apply not just to new homes, but existing homes as well.
The industry is still hashing out how the mortgage subsidy program would work. One potential glitch is that Ginnie Mae no longer buys mortgage loans; it guarantees payment for investors on pools of government-insured loans that are packaged into securities.
The mortgage finance companies Fannie Mae (FNM) and Freddie Mac (FRE) could somehow play a role now that the government runs them, Dugas suggested.
The industry insists that home buyers not be required to reimburse the government for the tax credit.
Lawrence Yun, the chief economist for the National Association of Realtors, said the requirement to pay back the government was "a huge psychological barrier" of the $7,500 tax credit geared toward first-time home buyers.
"As currently structured, people don't see it as a tax credit, but as an additional loan they have to repay," he said.
-By Jessica Holzer, Dow Jones Newswires; 202-862-9228; jessica.holzer@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=h4DiqbZI5m8YiTabAal5Ag%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
October 28, 2008 07:36 ET (11:36 GMT)
Copyright (c) 2008 Dow Jones & Company, Inc.- - 07 36 AM EDT 10-28-08
Actually he walked away - er was shown the door - with his regular salary of 175k, of which a portion was paid by others, and a pocket full of options that were most likely extinguished with his termination. Even if he retained the options, they must be purchased at exercise prices ranging from $.18 to $2.60.
A portion of Mr. MacDonald's time is spent assisting with the research programs of Biomed Solutions, LLC and Myotech, LLC, related companies, for which Biophan is reimbursed.
http://people.forbes.com/profile/stuart-g-macdonald/11895
I stand by my claim of significant expense reduction.
It's ok Spot - there are still folks that don't believe the Titans are for real either. It's the final score, of course, that determines the outcome, and this game isn't over.
Titans 31 -- Colts 21
7-0 baby!!!
Biophan - Myotech listed in table of contents. Only $4500 for the report, whose gonna take one for the team?
I vote for SS :)
Biophan Technologies Incorporated Page 188
The market for
ventricular-assist devices will continue to
grow moderately, spurred by widening
applications in the management of pretransplant
and late-stage heart conditions.
http://www.freedoniagroup.com/brochure/23xx/2398smwe.pdf
http://www.freedoniagroup.com/(S(4oul4k45ryhjfp55hfvfdg3e))/DocumentDetails.aspx?DocumentId=419789
Go Titans!!!
"A man doesn't know what he knows until he knows what he doesn't know"
Significant expense reduction here.
Stuart G. MacDonald
Divisional Vice President
Biophan Technologies, Incorporated
Pittsford , NY
Sector: HEALTHCARE / Medical Instruments & Supplies
Officer since January 2001
58 Years Old
Stuart G. MacDonald has been Biophan's Vice-President-Research and Development since January 2001. From January 1995 through December 2000, Mr. MacDonald was employed at Ortho-Clinical Diagnostics, a Johnson & Johnson company, holding the position of Director-Engineering from 1996 to mid-1997 and Vice-President, Clinical Lab Instrumentation R&D from mid-1997 through December 2000. He worked at Eastman Kodak Company from 1971 to 1994, rising to the position of Assistant Director, Clinical Diagnostic Research Labs. A portion of Mr. MacDonald's time is spent assisting with the research programs of Biomed Solutions, LLC and Myotech, LLC, related companies, for which Biophan is reimbursed. On September 15, 2008, Stuart G. MacDonald, the Company's Vice President - Research and Development, was given notice his employment is being terminated effective October 15, 2008.
Compensation
Salary $175,000.00
Bonus $0.00
Other Annual Compensation $0.00
Long term incentive plan payouts $0.00
Restricted stock awards $0.00
Security underlying options $0.00
All other compensation $0.00
Option awards $ $152,600.00
Non-equity incentive plan compensation $0.00
Change in pension value and nonqualified deferred compensation earnings $0.00
Total Compensation $327,600.00
Options Granted during Fiscal Year
Grant
Date All other stock awards (# of shares of stocks or units) Number of securities underlying options Exercise
or base
price Percent of total options granted in fiscal year Grant date fair value of stock and option awards See More
07/27/2008 - 545,000 $0.28 7.76% $ -
Options Exercised
Number of securities underlying options exercisable 715,000
Number of securities underlying options unexercisable 135,000
Value of unexercised options, currently exercisable $681,800.00
Value of unexercised options, currently unexercisable $129,950.00
FINAL COMPENSATION $ 327,600.00
http://people.forbes.com/profile/stuart-g-macdonald/11895
Biophan to dissolve subsidiary
By SMRITI JACOB
Rochester Business Journal
October 24, 2008
Biophan Technologies Inc. has elected to dissolve its subsidiary Myotech LLC, the company reported in documents filed with the Securities and Exchange Commission.
The filing states Biophan has given written notice to Myotech and plans to distribute the assets in accordance with the operating agreement for the limited liability company. The decision was made Oct. 17; Biophan filed documents with the SEC Thursday.
Myotech will transfer substantially all of its assets to Biophan, the filing states, including the securities purchase agreement between the two companies. After the transfer, Biophan will have no further funding obligations under the agreement, SEC documents show. Biophan officials were not immediately available for comment.
The Pittsford company has been investing millions of dollars in Myotech—$7.8 million at last count—to aid the development of that firm’s circulatory support system that claims to completely restore cardiac output from an arrested heart. Myotech was formed in July 2003 to commercialize a circulatory support system based on a family of technologies called direct mechanical ventricular actuation, previous documents filed by Biophan with the SEC show. Biophan assumed a minority interest in Myotech in late 2005 and subsequently increased its ownership to more than 70 percent.
In the filing Biophan said it has retained ownership of the Myotech CSS technology, and that it remains committed to finding development and distribution partners that will further the commercialization of the technology.
Biophan, which trades over-the-counter under the symbol BIPH.OB, calls itself a technology development and holding company focused on the creation and sale of novel patent-protected technologies and medical devices.
http://www.rbj.net/fullarticle.cfm?sdid=75663&fromsearch=1
Dr. T this link has quite a lot of additional reading material regarding the Myotech CSS device. This patent application is divisional to the utility patent that was recently allowed. This application was filed in 2006 and contains more recent information.
advance warning - takes awhile to read, lots of information.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=359542.APN.&OS=APN/359542&RS=APN/359542
"A man doesn't know what he knows until he knows what he doesn't know"
Barcode boarding on NBC Nightly News - Sunday.
http://www.msnbc.msn.com/id/21134540/vp/27389649#27389649
"A man doesn't know what he knows until he knows what he doesn't know"
Pickens Plan on 60 Minutes this Sunday
Don't think so -- AS is 250mm and OS is 243mm -- AS is pretty well maxed out.
Damn thats worse than the I know you know that I know stuff. lol
Seems like a pretty solid business plan to me. Purchase $26mm worth of patents for $3.2mm. It's worth the time to read (reread) the SPA associated with this filing, Exhibit 10.1 as it was first published more than a year ago.
To all the old timers here, forgive me while I play a little catch up.
http://www.biophan.com/index.php?option=com_content&task=view&id=429&Itemid=446
Item 1.01 Entry into a Material Definitive Agreement.
On October 2, 2007, Biophan Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with Myotech, LLC, a New York limited liability company (“Myotech”), pursuant to which the Company agreed to purchase from Myotech an aggregate of 15,496,547 membership units for an aggregate purchase price of $3,200,000. Prior to the execution of the Agreement Biophan owned 5,408,194 Class A Membership Units of Myotech. In accordance with the Agreement, upon execution of the Agreement Biophan received 5,000,000 Class A Membership Units and was to receive an addition 4,316,547 Class A Membership Units upon the payment of an aggregate initial purchase price of $1,200,000. Thereafter, upon the satisfaction of certain conditions, Biophan would purchase an additional 6,180,000 Class A Membership Units of Myotech for a purchase price of $2,000,000. As a result of this investment the Company’s holdings in Myotech will increase to 68 percent from 44 percent prior to the deal and provide Biophan with control of a majority of the Board of Directors of Myotech.
Myotech is a private company developing a novel circulatory support device that is designed to restore full cardiac output from an arrested heart. Myotech's technology addresses one of the most significant unmet needs in healthcare, acute circulatory support for patients suffering from sudden cardiac arrest. Today in the United States, over 260,000 patients suffer in-hospital cardiac arrest every year, and about 80 percent of those patients do not survive. The Company anticipates that the Myotech Circulatory Support System (CSS) will dramatically improve these outcomes.
http://www.sec.gov/Archives/edgar/data/1084000/000114420407052986/v089616_8-k.htm
http://www.sec.gov/Archives/edgar/data/1084000/000114420407052986/v089616_ex10-1.htm
"A man doesn't know what he knows until he knows what he doesn't know"
Interesting pal, I had not seen that.
Thanks doc T for your response to my questions promising tech indeed.
Yes bubba, I gotta give you that, but I'm thinking the quality of life may not be real good so long as you have an external pump forcing blood through your body even if it is easily inserted and evacuates fluid build up by design lol. I'm really more interested in an opinion regarding the improved probability that the patients heart will once again beat on it's own because additional time for treatment has been achieved by using this device.
"A man doesn't know what he knows until he knows what he doesn't know"
Don't know -- There was no litigation search prior to the last office action but there was prior to the reexam order. Probably standard procedure is my guess.
Patent Application Information Retrieval
SYSTEM AND METHOD FOR AUTOMATIC ACCESS OF A REMOTE COMPUTER OVER A NETWORK
Transaction History
Date Transaction Description
10-22-2008 Reexam Litigation Search Conducted
Doc, do you have an opinion as to the medical benefit for a patient requiring this device as opposed to current treatment options? I have read that survival rates are currently very low when CPR etc. is required. TIA
I realize it's hard to know what ya don't know, nevertheless, I would like to know what ya do know!
Bad week to be a colt's fan
NEWS !!!
BEAVERTON, Ore., Oct 23, 2008 (BUSINESS WIRE) -- Hydra Fuel Cell Corporation
(www.hydrafuelcell.com), a wholly owned subsidiary of American Security
Resources Corporation (OTCBB:ARSC), announced today that it has been notified by
the U.S. Patent Office that its first patent will be issued on or about November
4, 2008, and is expected to carry US Patent No. 7,445,647.
Jim Twedt, President and CEO of Hydra, said, "This patent is titled 'Method for
Making a Single Unit Fuel Cell' and was central to the unique design we were
developing. Our fuel cell technology has advanced significantly since then,
overcoming some daunting scientific, technical and engineering challenges in the
process of becoming what we believe is the most advanced, affordable and
economical fuel cell to come to market."
Twedt continued, "We are assembling a commercial unit to send to
CSA-International to complete our certification process, after which we will
begin production to deliver to our $21,000,000 purchase order backlog."
American Security Resources Corporation
ARSC is a holding company developing clean energy technologies. Its Hydra Fuel
Cell Corp. subsidiary is developing high volume, mass producible hydrogen fuel
cells. Its American Hydrogen Corp. subsidiary is developing a method to
inexpensively formulate hydrogen from ammonia. For more information, please see:
www.americansecurityresources.com
Safe Harbor Statement
This news release contains certain "forward-looking statements" within the
meaning of Section 27a of the Securities Act of 1933 and Section 21e of the
Securities Exchange Act of 1934. Although the Company believes the expectations
reflected in such forward-looking statements are reasonable, it can provide no
assurance that actual results will meet or exceed such expectations.
SOURCE: Hydra Fuel Cell Corporation
CONTACT:
Hydra Fuel Cell Corporation
Jim Twedt, 503-645-2523
info@hydrafuelcell.com
or
American Security Resources Corporation
Frank Neukomm or Bob Farr, 713-465-1001
info@amsrcorp.com
Copyright Business Wire 2008
-0-
Here you go Bubba, I think this is what you are referring to.
I'm pretty sure your calculations would be called the "per share value of cash on hand" which of course has very little to do with the intrinsic value of the company. There is a risk reward profile here that I am comfortable living with. I will choose to make my own decisions although I do value the input of others. I see no personal reward from being in a position to say "I told you so" however, I do understand that it is important to some.
Regards,
"A man doesn't know what he knows until he knows what he doesn't know"
This is most likely where they Myotech valuations came from.
The Company has recently re-evaluated the accounting treatment of its investment in MYOTECH. In order to comply with FASB FIN 46(R), the Company has consolidated MYOTECH from the date of acquisition, November 30, 2005. In order to accomplish this consolidation, the Company had the patents held by MYOTECH appraised by a nationally-recognized, independent, outside valuation firm.
The patents that MYOTECH holds were appraised at $26 million, which is now included in the Company’s consolidated balance sheet.
http://www.biophan.com/index.php?option=com_content&task=view&id=429&Itemid=446
The end of this story hasn't been written, but a date is approaching.
U.S. District Court
United States District Court for the Southern District of New York (Foley Square - Suspense)
CIVIL DOCKET FOR CASE #: 2:04-cv-03026-JES
NeoMedia Technologies, Inc. v. Scanbuy Inc.
Assigned to: Judge John E. Sprizzo
Cause: 35:271 Patent Infringement
Date Filed # Docket Text
07/09/2008 42 JOINT STATUS REPORT (ORDER): A status report will again be submitted to the Court ten days in advance of the yet unscheduled status hearing in early November 2008. (Signed by Judge John E. Sprizzo on 7/8/08) (db) (Entered: 07/09/2008)
MBD's assumptions regarding current book value @ $.09 are very valid as they come directly from the latest 10Q.
Class outstanding as of October 10, 2008 - Common Stock, $.005 par value: 243,285,264 shares
Total liabilities and stockholders' equity $ 23,221,458
23,221,458 divided by 243,285,264 = $0.095
http://ih.advfn.com/p.php?pid=nmona&cb=1224607671&article=28721906&symbol=NB%5EBIPH
GLTU regarding recovery of your cost basis. I feel very fortunate to have a cost basis of $.0125 for the time being.
However I sometimes suffer from dilusional optimism, perhaps I need a Dr. to help keep me grounded. lol
Regards,
How bout them Titans
"A man doesn't know what he knows until he knows what he doesn't know"
Related Info
http://www.who.int/impact/activities/Toedtli.pdf
http://www2.markenpiraterie-apm.de/files/standard/SAP_APM%20Kongress%202008.pdf
CLEPA barcode = new functionality for Neoreader or a variant of Data Matrix?
"A man doesn't know what he knows until he knows what he doesn't know"
New PR firm for NEOM?
http://www.the-cc-group.com/
The news could equal a lot of downloads/clicks. Wonder if there is revenue?
Authentication - anti-counterfeiting could be a very large market.
Thanks for posting BTW
"A man doesn't know what he knows until he knows what he doesn't know"
Pickens' natural gas idea picking up steam
Will cars be fueled by CNG? Yes, if ex-oil tycoon has any say in the matter
http://www.msnbc.msn.com/id/27052462/
Fannie, Freddie CEOs discuss foreclosures
Pair tell mortgage bankers their agencies must do more to stem crisis
http://www.msnbc.msn.com/id/27286282/
From another company's SEC filing, -- should answer the question about whether a shareholder meeting/vote is required for a RS.
This Information Statement has been filed with the Securities and Exchange Commission and is being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the holders (the "Stockholders") of outstanding shares of capital stock, of XXXXX, Inc., a Delaware Corporation (the "Company”) to advise you of an action which has already been approved by a majority in interest of the stockholders of the Company (the “Action”), namely, an amendment to the Company's Certificate of Incorporation (the "Amendment") which effects a 1-for-25 reverse split of our Common Stock.
The Company's Board of Directors, on July 16, 2008, approved the Amendment and recommended that the Amendment be approved by written consent of a majority in interest of our stockholders.
In order to accelerate the Action and to reduce the costs of obtaining stockholder approval, our Board of Directors elected to obtain such approval by utilizing the written consent of the holders of a majority in interest of our capital stock (the “Consent”). The elimination of the need for a special meeting of stockholders to approve the Action is made possible by Section 228 of the Delaware General Corporation Law (the "Delaware Law") which provides that the written consent of the holders of outstanding shares of voting capital stock, having not less than the minimum number of votes which would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted, may be substituted for such a special meeting.
Pursuant to Section 242 of the Delaware Law, the Amendment is required to be approved by a majority in interest of our stockholders. In accordance with Rule 14c-2(b) under the Securities Exchange Act of 1934, as amended, the corporate action can be taken no sooner than 20 calendar days after this Information Statement is first mailed to the stockholders of the Company. If the proposed action was not adopted by written consent, it would have to be considered by the Company's stockholders at a special stockholders' meeting convened for the specific purpose of approving the Action upon the expiration of the 20-day period set forth above.
On or about July 16, 2008, Stockholders, who own in the aggregate 29,365,500 shares of our Common Stock and 1,000,000 shares of our Series A Preferred Stock, representing in the aggregate approximately 59.2% of the voting rights of our outstanding shares (after giving effect to the voting rights of our Series A Preferred stock) gave their written consent to the adoption of the Action. The proposed Amendment will become effective when filed with the Secretary of State of the State of Delaware upon the expiration of the 20-day period set forth above.
Botte patent allowed by USPTO
Patent Application Information Retrieval
10/962,894 ELECTRO-CATALYSTS FOR THE OXIDATION OF AMMONIA IN ALKALINE MEDIA
Bibliographic Data
Application Number: 10/962,894 Customer Number: -
Filing or 371 (c) Date: 10-12-2004 Status: Notice of Allowance Mailed -- Application Received in Office of Publications
Application Type: Utility Status Date: 10-08-2008
Examiner Name: BELL, BRUCE F Location: ELECTRONIC
Group Art Unit: 1795 Location Date: -
Confirmation Number: 9775 Earliest Publication No: US 2005-0211569 A1
Attorney Docket Number: 27211/04075 Earliest Publication Date: 09-29-2005
Class / Subclass: 204/293 Patent Number: -
First Named Inventor: Gerardine Botte , Athens, OH (US) Issue Date of Patent: -
--------------------------------------------------------------------------------
Title of Invention: ELECTRO-CATALYSTS FOR THE OXIDATION OF AMMONIA IN ALKALINE MEDIA
LOL not exactly, but I wonder how say Papa John's would react to 10,000 emails, letters, phone calls from unhappy shareholders asking them to stop supporting NEOM or risk loosing the goodwill of those folks towards Papa? YA would not be holding much of an asset if the limited number of supporters withdrew their support.
"A man doesn't know what he knows until he knows what he doesn't know"
I'm not talking about a litigation!
If the shareholders of this company turn against it with the same fervor as they have supported it over the years, YA may just end up with nothing too. If they attempt to seize the assets due to default regarding failure to deliver shares, this particular army of one will be ready for battle.
Time to change your sig YJ - Count me in!!
SUBSEQUENT EVENTS:
On September 24, 2008, Biophan Technologies, Inc. (the “Company”) announced execution of a prepayment agreement with the holders of its Senior Secured Convertible Notes. Pursuant to the prepayment agreement, the holders of the Secured Convertible Notes accepted a prepayment of the remaining $2.3 million in senior debt, in exchange for an aggregate cash payment of $2.15 million plus delivery of 18 million shares of the Company’s common stock. In connection with this transaction, note holders were offered additional shares in exchange for surrendering their warrants to purchase the Company’s common stock, issued in connection with the Senior Secured Convertible Notes.. Warrants to purchase 17 million shares of common stock were redeemed leaving outstanding warrants to purchase 23 million shares of the Company’s common stock All of the remaining warrants have an exercise price of $0.23 per share.
23mm warrants at $.23 = $5,290,000 in potential additional funding. Hope these warrants get exercised soon. :)
Just a side note; The Titans are the only unbeaten team in the NFL
If I'm not mistaken, the 243 mm number includes committed but not yet issued shares allocated to warrants and options.